SCHEMBL2842664

SCHEMBL2842664

COCCN(C)C(=O)/N=c1\sc(C)cn1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.41
CNR1 P21554 2/20 0.41
SCN9A Q15858 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
USP30 Q70CQ3 1/20 0.33
HDAC4 P56524 1/20 0.33
GAA P10253 1/20 0.33
ALOX12 P18054 1/20 0.33
MALT1 Q9UDY8 1/20 0.32
PPARD Q03181 3/20 0.32
PPARA Q07869 3/20 0.32
PPARG P37231 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.32
CXCR3 P49682 1/20 0.32
MLYCD O95822 1/20 0.32
NR3C1 P04150 1/20 0.32
HSP90AA1 P07900 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2842668 1.00 CNR2 (0.41) CNR2CNR1SCN9AGPR119USP30
SCHEMBL2846619 0.91 CNR2 (0.42) CNR2CNR1SCN9AUSP30GAA
SCHEMBL2846614 0.91 CNR2 (0.42) CNR2CNR1SCN9AUSP30GAA
SCHEMBL2837583 0.90 CNR2 (0.40) CNR2CNR1SCN9AUSP30GAA
SCHEMBL2837581 0.90 CNR2 (0.40) CNR2CNR1SCN9AUSP30GAA
SCHEMBL2870065 0.88 CNR2 (0.35) CNR2CNR1PPARDPPARAPPARG
SCHEMBL2870061 0.88 CNR2 (0.35) CNR2CNR1PPARDPPARAPPARG
SCHEMBL2873991 0.88 UTS2R (0.33) CNR2CNR1PPARDPPARAPPARG
SCHEMBL2873987 0.88 UTS2R (0.33) CNR2CNR1PPARDPPARAPPARG
SCHEMBL2861874 0.88 CNR2 (0.36) CNR2CNR1PPARDPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2245020-B1 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF ABBVIE INC (US) 2014-01-15 EP claimed
EP-2245020-A2 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF Abbott Laboratories (US) 2010-11-03 EP claimed
US-20090221648-A1 COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS ABBOTT LABORATORIES (US) 2009-09-03 US claimed
WO-2009086163-A2 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-07-09 WO claimed
US-20090163470-A1 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-06-25 US claimed
EP-2245020-B1 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF ABBVIE INC (US) 2014-01-15 EP disclosed
US-8383657-B2 Thiazolylidine urea and amide derivatives and methods of use thereof ABBOTT LABORATORIES (US) 2013-02-26 US disclosed
EP-2245020-A2 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF Abbott Laboratories (US) 2010-11-03 EP disclosed
US-20090221648-A1 COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS ABBOTT LABORATORIES (US) 2009-09-03 US disclosed
WO-2009086163-A2 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-07-09 WO disclosed
WO-2009082698-A1 COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS ABBOTT LABORATORIES (US) 2009-07-02 WO disclosed
US-20090163470-A1 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163470-A1 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF NMUR1, NMUR2, PAM CNR2 156/4885CNR1 191/4885SCN9A 267/4885
US-20090221648-A1 COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS CHRNA4, CHRNA5, CHRNA3 CNR2 91/4885CNR1 112/4885SCN9A 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.